Comparative Pharmacology
Head-to-head clinical analysis: ALPHAGAN versus CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAGAN versus CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE.
ALPHAGAN vs CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Clonidine is an alpha-2 adrenergic agonist that reduces sympathetic outflow from the CNS, decreasing peripheral resistance and heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
1 drop of 0.1% or 0.15% solution in the affected eye(s) three times daily, approximately 8 hours apart.
Oral: 1 tablet (0.1 mg clonidine/15 mg chlorthalidone) once daily, titrated up to maximum 4 tablets daily.
None Documented
None Documented
2.5-3.0 hours in adults; in renal impairment, half-life is prolonged (up to 6 hours).
Clonidine: 12.7-16.9 hours (terminal), prolonged in renal impairment (up to 40 hours). Chlorthalidone: 40-60 hours (terminal), allowing once-daily dosing.
Renal: approximately 70-80% as unchanged drug and metabolites; fecal: 5-10%.
Clonidine: ~40-60% excreted unchanged in urine, remainder as metabolites; renal elimination accounts for ~50-65% of total clearance. Chlorthalidone: ~50-65% excreted unchanged in urine, with ~30-50% undergoing renal tubular secretion; minimal biliary/fecal elimination (<10%).
Category C
Category A/B
Alpha-2 Agonist
Alpha-2 Agonist